Jakubowitz Law
22.7.2021 11:43:15 CEST | ACCESS Newswire | Press release
NEW YORK, NY / ACCESSWIRE / July 22, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.
RLX Technology Inc. (NYSE:RLX)
CONTACT JAKUBOWITZ ABOUT RLX:
https://claimyourloss.com/securities/rlx-technology-inc-loss-submission-form/?id=17871&from=1
This lawsuit is on behalf of persons who purchased, or otherwise acquired, RLX American Depository Shares pursuant or traceable to the documents issued in connection with RLX's January 2021 initial public stock offering.
Lead Plaintiff Deadline: August 9, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: the Company's then-existing exposure to China's ongoing campaign to establish a national standard for e-cigarettes, which would bring them into line with ordinary cigarette regulations, and that RLX's reported financials were not nearly as robust as the offering materials projected, nor were they indicative of future results. As a result, investors purchased RLX shares at artificially inflated prices.
DraftKings Inc. f/k/a Diamond Eagle Acquisition Corp. (NASDAQ:DKNG)
CONTACT JAKUBOWITZ ABOUT DKNG:
https://claimyourloss.com/securities/draftkings-inc-f-k-a-diamond-eagle-acquisition-corp-loss-submission-form/?id=17871&from=1
Class Period : December 23, 2019 - June 15, 2021
Lead Plaintiff Deadline: August 31, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) SBTech Global Limited ("SBTech"), a company acquired by DraftKings, had a history of unlawful operations; (ii) accordingly, DraftKings' merger with SBTech exposed the Company to dealings in black-market gaming; (iii) the foregoing increased the Company's regulatory and criminal risks with respect to these transactions; (iv) as a result of all the foregoing, the Company's revenues were, in part, derived from unlawful conduct and thus unsustainable; (v) accordingly, the benefits of the Business Combination were overstated; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.
Didi Global Inc. F/K/A Xiaoju Kuaizhi Inc. (NYSE:DIDI)
CONTACT JAKUBOWITZ ABOUT DIDI:
https://claimyourloss.com/securities/didi-global-inc-f-k-a-xiaoju-kuaizhi-inc-loss-submission-form/?id=17871&from=1
This lawsuit is on behalf of persons and entities that purchased or otherwise acquired DiDi: (a) American Depositary Shares pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's June 2021 initial public offering; and/or (b) securities between June 30, 2021 and July 2, 2021, inclusive.
Lead Plaintiff Deadline: September 7, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) DiDi's apps did not comply with applicable laws and regulations governing privacy protection and the collection of personal information; (2) as a result, the Company was reasonably likely to incur scrutiny from the Cyberspace Administration of China; (3) the CAC had already warned DiDi to delay its IPO to conduct a self-examination of its network security; (4) as a result of the foregoing, DiDi's apps were reasonably likely to be taken down from app stores in China, which would have an adverse effect on its financial results and operations; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
SOURCE: Jakubowitz Law
View source version on accesswire.com:
https://www.accesswire.com/656624/LAWSUITS-FILED-AGAINST-RLX-DKNG-and-DIDI--JAKUBOWITZ-LAW-PURSUES-SHAREHOLDERS-CLAIMS
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
OBI Pharma Announces Ten Poster Presentations at the AACR 2026 Annual Meeting for GlycOBI(R) Glycan-based Site-Specific Antibody-Drug Conjugates (ADCs): Mono and Bi-Specific (inc. Dual payload) and Obrion(TM) ADC enabling technologies15.4.2026 10:40:00 CEST | Press release
Poster Presentations featuring the latest advancements on anti-TROP2 (OBI 902) and Nectin-4 (OBI 904) ADCs, anti-TROP2/HER2 BsADC (OBI 201), anti-cMET/HER3Bs-Dual Payload ADC (OBI 221),and OBI's novel Obrion ™ ADC enabling technologies(GlycOBI ® and GlycOBI DUO ®). TAIPEI, TW / ACCESS Newswire / April 15, 2026 / OBI Pharma, Inc. (TPEx:4174.TWO) today announced its presence at AACR 2026, highlighted by ten poster presentations, showcasing the transformative potential of the GlycOBI® platform. Conventional ADCs often face limitations due to random conjugation, resulting in heterogeneous Drug-to-Antibody Ratios (DAR), suboptimal stability, and narrow therapeutic windows. In contrast, the OBI site-specific glycan-based technology enables a highly homogeneous DAR, translating into improved PK/PD profiles, and reduced off-target toxicity, as demonstrated by OBI's lead programs, OBI-902 and OBI-904. We are further advancing precision oncology through our next-generation bispecific (OBI-201) a
OBI Pharma Announces Ten Poster Presentations at the AACR 2026 Annual Meeting for GlycOBI(R) Glycan-based Site-Specific Antibody-Drug Conjugates (ADCs): Mono and Bi-Specific (inc. Dual payload) and Obrion(TM) ADC enabling technologies15.4.2026 10:40:00 CEST | Press release
Poster Presentations featuring the latest advancements on anti-TROP2 (OBI 902) and Nectin-4 (OBI 904) ADCs, anti-TROP2/HER2 BsADC (OBI 201), anti-cMET/HER3Bs-Dual Payload ADC (OBI 221),and OBI's novel Obrion ™ ADC enabling technologies(GlycOBI ® and GlycOBI DUO ®). TAIPEI, TW / ACCESS Newswire / April 15, 2026 / OBI Pharma, Inc. (TPEx:4174.TWO) today announced its presence at AACR 2026, highlighted by ten poster presentations, showcasing the transformative potential of the GlycOBI® platform. Conventional ADCs often face limitations due to random conjugation, resulting in heterogeneous Drug-to-Antibody Ratios (DAR), suboptimal stability, and narrow therapeutic windows. In contrast, the OBI site-specific glycan-based technology enables a highly homogeneous DAR, translating into improved PK/PD profiles, and reduced off-target toxicity, as demonstrated by OBI's lead programs, OBI-902 and OBI-904. We are further advancing precision oncology through our next-generation bispecific (OBI-201) a
IDC Defines the Next Era of Technology Intelligence with the Introduction of IDC Quanta(TM) at Directions 20268.4.2026 17:15:00 CEST | Press release
New AI-powered platform establishes an embedded intelligence layer for the AI economy, delivering decision-grade insight BOSTON, MA / ACCESS Newswire / April 8, 2026 / IDC today opened IDC Directions 2026, its flagship client event, bringing together technology leaders, analysts, and industry experts to examine the forces reshaping the global technology market and to introduce a major evolution in how technology intelligence is delivered. At the center of this year's event is IDC Quanta™, a new AI-powered platform that establishes what IDC defines as the technology intelligence layer for the AI economy. As artificial intelligence accelerates the pace of business and compresses decision cycles, IDC is redefining its role from a destination for research and data to an embedded intelligence capability that delivers trusted insight directly into the workflows where decisions are made. "AI is compressing time across the entire technology market, and that breaks the traditional research mode
DistillerSR Launches the Industry's Most Advanced GenAI Capabilities for Extracting Scientific Literature Evidence8.4.2026 16:00:00 CEST | Press release
DistillerSR's Smart Evidence Extraction Now Fully Automates Text and Table Data at Scale OTTAWA, ON / ACCESS Newswire / April 8, 2026 / DistillerSR, the market leader in AI-enabled literature review automation and evidence management, today announced new fully automated capabilities for its Smart Evidence Extraction (SEE) module. SEE uses purpose-built GenAI to automate end‑to‑end workflows for extracting evidence from scientific literature at scale, while maintaining full auditability and human governance over AI‑generated outputs. As the volume of published research continues to grow exponentially, research teams in the pharmaceutical and medical device industries face increasing pressure to monitor evidence with speed and precision. SEE enables research professionals to accurately find, suggest, explain, extract, and link the supporting evidence within the reference in a human-in-the-loop and fully automated workflow. "The latest version of SEE is designed to move research teams fro
Envision Pharma Group appoints Nick Jones as President, Envision Medical Communications8.4.2026 14:00:00 CEST | Press release
Seasoned technology and life sciences leader to advance AI integration across medical communications FAIRFIELD, CT / ACCESS Newswire / April 8, 2026 / Envision Pharma Group (Envision), a global, technology-enabled solutions partner to the life sciences industry, today announced the appointment of Nick Jones as President, Envision Medical Communications (EMC). In this role, Jones will lead the EMC business, focusing on integrating Envision's industry-leading technology and AI capabilities into its award-winning portfolio of solutions and services. Jones joins the company from ConcertAI, where he served as Senior Vice President and General Manager, Commercial Solutions, leading teams delivering consulting services, AI-driven software-as-a-service solutions, and data products supporting pharmaceutical commercialization. Prior to ConcertAI, he spent over a decade at IQVIA (formerly IMS), leading technology and consulting organizations across the US, Europe, and JAPAC, delivering an integra
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
